Frontlight ResearchEarly access
Atopic dermatitis (eczema) trials in United States
52 of 76 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleEvaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
- Where
- Bethesda
- Age
- 12 years to 120 years
- People
- 20
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
See details and how to joinNCT07262983 - Phase 2Taking peopleEffects of Treatments on Atopic Dermatitis
- Where
- Bethesda
- Age
- 2 years to 50 years
- People
- 130
- Run by
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
See details and how to joinNCT01631617 - Phase 3Taking peopleA Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
- Where
- Bakersfield, Birmingham, Dallas, Fargo, Fountain Valley, Marietta, Miami, Northridge, Panama City, San Diego, Savannah, Scottsdale, Southlake, St. Petersburg, West Hills
- Age
- 12 years and over
- People
- 375 worldwide
- Run by
- Pfizer
See details and how to joinNCT07765888 · EU 2026-526155-65-00 - No phaseTaking peopleMichigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
- Where
- Ann Arbor
- Age
- 10 years to 55 years
- People
- 200
- Run by
- University of Michigan
See details and how to joinNCT06300697 - Phase 3Taking peopleA Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Where
- Birmingham, Charleston, Jacksonville, Macon, Miami, Norfolk, North Little Rock, Palo Alto, Portland, Sacramento, San Diego, Tampa, Tulsa, Waterford
- Age
- 6 months to 11 years
- People
- 195 worldwide
- Run by
- LEO Pharma
See details and how to joinNCT06311682 · EU 2023-503630-44-00 - Early phase 1Enrolling by invitationThera-Clean® Microbubbles System in Patients With Skin Diseases
- Where
- Chicago
- Age
- 2 years and over
- People
- 20
- Run by
- Northwestern University
See details and how to joinNCT07050810 - Phase 1Taking peopleFirst-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Where
- Birmingham, Miami, North Charleston, North Little Rock, San Antonio, Union City, West Hills, Weston
- Age
- 18 years to 65 years
- People
- 160 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07527923 · EU 2025-524205-32-00 - Phase 3Taking peopleA Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
- Where
- Arlington, Bakersfield, Birmingham, Boise, Bryant, Camp Hill, Dallas, East Syracuse, Fountain Valley, Hialeah, Huntington Beach, Hunt Valley, Indianapolis, Laguna Niguel, Los Angeles, Macon, Marietta, Memphis, Miami, Miami Lakes, Northridge, Orlando, Phoenix, Portland, Santa Ana, Southlake, Sugar Land, Tampa, Troy, Tulsa, Ypsilanti
- Age
- 12 years and over
- People
- 1,375 worldwide
- Run by
- Pfizer
See details and how to joinNCT07783425 · EU 2026-525743-32-00 - Phase 3Taking peopleRoflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
- Where
- Birmingham, Bryant, Chicago, Miami Lakes
- Age
- 6 years and over
- People
- 415
- Run by
- Arcutis Biotherapeutics, Inc.
See details and how to joinNCT07916480 - Phase 1Taking peopleFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- Where
- Anaheim, Miami, Philadelphia, San Diego, Troy
- Age
- 18 years to 70 years
- People
- 119 worldwide
- Run by
- Pfizer
See details and how to joinNCT06564389 · EU 2025-524150-34-00 - Phase 3Taking peopleA Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Where
- Birmingham, Charleston, Greenville, Indianapolis, Jacksonville, Meridian, North Little Rock, San Antonio, San Diego, St Louis
- Age
- 2 years to 11 years
- People
- 450 worldwide
- Run by
- Pfizer
See details and how to joinNCT06807281 · EU 2023-509124-18-00 - Phase 2Taking peopleA Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
- Where
- Huntington Beach, Lorain, Los Angeles, Margate, Mayfield Heights, Miami, Northridge, Philadelphia, Phoenix, Pittsburgh, Santa Monica, Scottsdale, The Bronx
- Age
- 18 years to 64 years
- People
- 165 worldwide
- Run by
- Pfizer
See details and how to joinNCT07216027 · EU 2025-522965-31-00 - Phase 2Taking peopleA Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Where
- Boardman, Bowling Green, Charleston, Coral Gables, Dallas, Detroit, Douglasville, Fountain Valley, Frisco, Jacksonville, Los Angeles, Margate, Mason, Mill Creek, Nashville, New York, Pittsburgh, Portland, Rockville, San Antonio, Skokie, Troy, Wilmington
- Age
- 18 years and over
- People
- 350 worldwide
- Run by
- Apogee Therapeutics, Inc.
See details and how to joinNCT07003425 - Phase 1Taking peopleA Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma
- Where
- New Haven
- Age
- 18 years to 65 years
- People
- 133 worldwide
- Run by
- Pfizer
See details and how to joinNCT07660731 · EU 2026-526260-21-00 - Phase 2Taking peopleCardamom and Topical Roseomonas in Atopic Dermatitis
- Where
- Bethesda
- Age
- 2 years to 100 years
- People
- 120
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
See details and how to joinNCT06096857 - Phase 2Taking peopleA Study Evaluating TRIV-573 in Atopic Dermatitis
- Where
- Bay City, Boardman, Boca Raton, Camp Hill, Fountain Valley, Indianapolis, Los Angeles, Miami, Myrtle Beach, San Antonio, Spokane
- Age
- 18 years to 75 years
- People
- 90 worldwide
- Run by
- Triveni Bio
See details and how to joinNCT07782333 - Phase 3Enrolling by invitationA Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
- Where
- Bay City, Bellaire, Birmingham, Boise, Boston, Charleston, Chicago, Fairborn, Farmington, Fountain Valley, Jacksonville, Lebanon, Los Angeles, Milwaukee, North Little Rock, Owensboro, Phoenix, Sacramento, San Antonio, Tampa, Ypsilanti
- Age
- 6 months to 18 years
- People
- 338 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05735483 · EU 2022-501478-21-00 - Phase 1Taking peoplePh 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
- Where
- College Station, Fair Lawn, Miami, Plainfield, San Antonio, South Jordan
- Age
- 18 years to 65 years
- People
- 125
- Run by
- Arcutis Biotherapeutics, Inc.
See details and how to joinNCT07453602 - No phaseTaking peopleDigital Mindfulness Meditation in Adolescents With Atopic Dermatitis
- Where
- New York
- Age
- 13 years to 17 years
- People
- 40
- Run by
- Weill Medical College of Cornell University
See details and how to joinNCT07746427 - Phase 3Taking peopleA Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
- Where
- Auburn Hills, Boca Raton, Boise, Bowling Green, Clifton, Fountain Valley, Lafayette, Los Angeles, Macon, New York, Normal, North Little Rock, Oklahoma City, Omaha, Owensboro, Phoenix, St. Petersburg, Tampa, Wilmington
- Age
- 12 years and over
- People
- 510 worldwide
- Run by
- Nektar Therapeutics
See details and how to joinNCT07690371 · EU 2025-524925-42-00 - Phase 2Taking peopleTreatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
- Where
- New York
- Age
- 12 years and over
- People
- 56
- Run by
- Icahn School of Medicine at Mount Sinai
See details and how to joinNCT07242638 - Phase 4Not yet taking people in United StatesAD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes
- Where
- City of Saint Peters, Crest Hill, Fairfax, Grand Rapids, Greensburg, Houston, Libertyville, Mobile, Vienna, Virginia Beach
- Age
- 12 years and over
- People
- 250
- Run by
- Forefront Dermatology S.C
See details and how to joinNCT07856134 - Phase 1Taking peopleA Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
- Where
- Irvine, New York, The Bronx
- Age
- 18 years to 72 years
- People
- 237 worldwide
- Run by
- Bambusa Therapeutics
See details and how to joinNCT06808477 · EU 2025-522918-23-00 - Phase 2Taking peoplePlatform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Where
- Arlington, Atlanta, Birmingham, Brighton, Brooklyn, Cypress, Dallas, Fort Smith, Fountain Valley, Houston, Los Angeles, Louisville, Macon, Miami, Portsmouth, Sacramento, Saint Joseph, San Antonio, Santa Ana, Santa Monica, St. Petersburg, Troy, Washington D.C.
- Age
- 18 years to 100 years
- People
- 224 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06947993 · EU 2024-519081-49-00 - Phase 2Taking peopleStudy of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Where
- Arlington, Atlanta, Auburn Hills, Bay City, Beverly Hills, Birmingham, Camp Hill, Canton, Chicago, Clarksville, Clinton Township, Fort Lauderdale, Fremont, Hot Springs, Houston, Las Vegas, Louisville, Mayfield Heights, Miami, Miramar, New Albany, New York, Norfolk, San Antonio, San Diego, Santa Monica, Warren, West Hills, West Lafayette, Wilmington
- Age
- 18 years to 75 years
- People
- 105
- Run by
- Enveda Therapeutics
See details and how to joinNCT07298395